WallStSmart

LivaNova PLC (LIVN)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 2437% more annual revenue ($36.36B vs $1.43B). MDT leads profitability with a 13.2% profit margin vs 7.5%. LIVN appears more attractively valued with a PEG of 0.93. MDT earns a higher WallStSmart Score of 62/100 (C+).

LIVN

Buy

52

out of 100

Grade: C-

Growth: 5.3Profit: 5.5Value: 6.0Quality: 5.5
Piotroski: 4/9Altman Z: 0.35

MDT

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LIVNUndervalued (+5.6%)

Margin of Safety

+5.6%

Fair Value

$70.39

Current Price

$81.43

$11.04 discount

UndervaluedFair: $70.39Overvalued
MDTUndervalued (+10.6%)

Margin of Safety

+10.6%

Fair Value

$91.75

Current Price

$87.54

$4.21 discount

UndervaluedFair: $91.75Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LIVN2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.938/10

Growing faster than its price suggests

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$106.61B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.1%8/10

Strong operational efficiency at 22.1%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

LIVN4 concerns · Avg: 2.3/10
Profit MarginProfitability
7.5%3/10

7.5% margin — thin

P/E RatioValuation
41.2x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-45.6%2/10

Earnings declined 45.6%

Altman Z-ScoreHealth
0.352/10

Distress zone — elevated risk

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.634/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : LIVN

The strongest argument for LIVN centers on Debt/Equity, PEG Ratio. Revenue growth of 14.3% demonstrates continued momentum. PEG of 0.93 suggests the stock is reasonably priced for its growth.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : LIVN

The primary concerns for LIVN are Profit Margin, P/E Ratio, EPS Growth. A P/E of 41.2x leaves little room for execution misses.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

LIVN carries more volatility with a beta of 0.86 — expect wider price swings.

LIVN is growing revenue faster at 14.3% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDT scores higher overall (62/100 vs 52/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

LivaNova PLC

HEALTHCARE · MEDICAL DEVICES · USA

LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?